EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Elexacaftor–Tezacaftor–Ivacaftor Improves Sinonasal Outcomes in Young Children With Cystic Fibrosis

Amanda L Stapleton, Adam Kimple, Jennifer L Goralski, Daniel M Beswick iD, Anshika Gupta, Douglas A Li, Barton F Branstetter, S Mehdi Nouraie, Amber D Shaffer iD, Brent Senior iD, Anna C Zemke iD

International Forum of Allergy & Rhinology · 2025

DOI: 10.1002/alr.23555 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Forum of Allergy & Rhinology, 2025. Verfasst von Amanda L Stapleton und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology - Head & Neck Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Sinusitis, Rhinitis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cystic Fibrosis Foundation, University of Pittsburgh.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Severe chronic rhinosinusitis (CRS) is a near universal manifestation of cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor (ETI) is an oral, small molecule, highly effective Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) corrector–potentiator drug. In people with cystic fibrosis age > 12 years, ETI improves sinonasal symptoms, endoscopy findings, polyp size, and radiologic findings. This study evaluates changes in CRS in children ages 6–12 years newly started on ETI.

Methods

This was a prospective, three center, pre–post study of 11 children age 6–11 years newly started on ETI. Study endpoints included the SN‐5 sinonasal health survey, Sniffin’ Kids olfaction test, a sinus computerized tomography (CT) scan, and nasal endoscopy with mucus sampling for full‐length 16S rRNA sequencing microbiome analysis. Study visits were conducted before ETI and at a median of 9 months after treatment initiation.

Results

ETI lead to improvement in symptoms, endoscopy scores and radiologic findings of CRS. Olfaction was below normal at baseline and did not improve. The sinonasal microbiome was dominated by typically commensal organisms before and after treatment for most participants. Additionally, Staphylococcus aureus was found in five participants at baseline and six participants on treatment.

Conclusions

ETI improves sinonasal symptoms and endoscopy findings in children 6–11 years of age. Olfaction did not improve with ETI treatment in this age group, suggesting that olfactory dysfunction associated with CF is established early in life. This younger cohort of pediatric patients presented with abundant Staphylococcus aureus and only very rare Pseudomonas aeruginosa at baseline or after treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsSinusitisRhinitisBenzodioxolesQuinolonesIndolesPyridinesPyrazolesHumansChildMaleFemaleDrug CombinationsTreatment OutcomeParanasal SinusesProspective StudiesChronic DiseaseChloride Channel AgonistsQuinolines

Stichwörter der Autor:innen

Pseudomonas aeruginosaStaphylococcus aureusendoscopyolfactionrhinosinusitis

Substanzen

AminophenolsDrug CombinationsBenzodioxolesQuinolonesIndolesPyridinesPyrazoleselexacaftor, ivacaftor, tezacaftor drug combinationChloride Channel AgonistsQuinolines

Autor:innen und Institutionen

  • Department of Otolaryngology - Head & Neck Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Otolaryngology - Head & Neck Surgery, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Division of Pediatric Pulmonology, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Department of Head and Neck Surgery, University of California Los Angeles, Los Angeles, California, USA.
  • Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Daniel M Beswick, Amber D Shaffer, Brent Senior, Anna C Zemke

Förderung

  • Cystic Fibrosis Foundation
  • University of Pittsburgh

Zitieren

APA

Stapleton, A. L., Kimple, A., Goralski, J. L., Beswick, D. M., Gupta, A., Li, D. A., Branstetter, B. F., Nouraie, S. M., Shaffer, A. D., Senior, B., & Zemke, A. C. (2025). Elexacaftor–Tezacaftor–Ivacaftor Improves Sinonasal Outcomes in Young Children With Cystic Fibrosis. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23555

Vancouver

Stapleton AL, Kimple A, Goralski JL, Beswick DM, Gupta A, Li DA, et al. Elexacaftor–Tezacaftor–Ivacaftor Improves Sinonasal Outcomes in Young Children With Cystic Fibrosis. International Forum of Allergy & Rhinology. 2025. doi:10.1002/alr.23555

BibTeX
@article{Stapleton2025,
  author = {Stapleton, Amanda L and Kimple, Adam and Goralski, Jennifer L and Beswick, Daniel M and Gupta, Anshika and Li, Douglas A and Branstetter, Barton F and Nouraie, S Mehdi and Shaffer, Amber D and Senior, Brent and Zemke, Anna C},
  title = {Elexacaftor–Tezacaftor–Ivacaftor Improves Sinonasal Outcomes in Young Children With Cystic Fibrosis},
  journal = {International Forum of Allergy & Rhinology},
  year = {2025},
  doi = {10.1002/alr.23555}
}
Kostenlos starten →